XORTX Therapeutics Inc. (XRTX)
| Market Cap | 2.56M +261.1% |
| Revenue (ttm) | n/a |
| Net Income | -2.66M |
| EPS | -0.56 |
| Shares Out | 6.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,241 |
| Open | 0.38625 |
| Previous Close | 0.3450 |
| Day's Range | 0.3456 - 0.4000 |
| 52-Week Range | 0.3450 - 1.4100 |
| Beta | 0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About XRTX
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th... [Read more]
Financial Performance
Financial StatementsNews
Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
Xortx Therapeutics (XRTX) announced the launch of production of drug material and tablet manufacturing to support the company’s XRx-026 program for the treatment of gout. This manufacturing supports a...
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEW...
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ●
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX...
XORTX Re-Engages Investor Relations Program
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TS...
XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company focused on gout and progressive kidney disease, announced the termination and postponement of its previously an...
Xortx Therapeutics terminates investor relations, marketing agreement
Xortx Therapeutics (XRTX) terminated its previously announced investor relations and marketing agreement dated May 13 with IR Agency LLC. The IR agreement had a 90-day term commencing May 18 and…
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused ...
XORTX Announces Termination and Postponement of Investor Relations Program
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
XORTX Therapeutics Registration statement: Q2 2026
XORTX Therapeutics filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
XORTX Therapeutics Registration statement: Q2 2026
XORTX Therapeutics filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
XORTX Announces Director Resignation
CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Appoints New Director
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Therapeutics Transcript: Transcript
The company is advancing a late-stage gout therapy for allopurinol-intolerant patients, targeting NDA submission within 12-14 months, and preparing to relaunch its ADPKD program. Both programs address large unmet needs, with strong clinical data, robust patent protection, and significant market potential.
XRTX Welcomes Mika Grasso as New Co-CEO for Finance and Public Markets
XRTX Welcomes Mika Grasso as New Co-CEO for Finance and Public Markets
Xortx Therapeutics announces Mika Grasso as co-CEO
Xortx Therapeutics (XRTX) announced the addition of Mika Grasso as co-CEO responsible for finance and public markets. Grasso has served as a director of the company since March 24. Grasso…
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exc...
XRTX Announces Public Offering of Shares
XRTX Announces Public Offering of Shares
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
Xortx Therapeutics (XRTX) announced the pricing of a public offering of 2.66M common shares at an offering price of $1.88 for gross proceeds of $5M, prior to deducting placement agent’s…
XORTX Announces US$5 Million Public Offering
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused...
XORTX Regains Nasdaq Compliance, Stock Up
(RTTNews) - XORTX Therapeutics Inc. (XRTX) announced that it has regained compliance with Nasdaq's continued listing requirements, a key step that allows the late-clinical-stage company to maintain it...
XRTX Achieves Nasdaq Compliance Following Share Price Recovery
XRTX Achieves Nasdaq Compliance Following Share Price Recovery